thioacetanilide and 1-2-4-triazole

thioacetanilide has been researched along with 1-2-4-triazole* in 1 studies

Other Studies

1 other study(ies) available for thioacetanilide and 1-2-4-triazole

Article	Year
Arylazolylthioacetanilide. Part 11: design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Medicinal chemistry (Shariqah (United Arab Emirates)), 2013, Volume: 9, Issue:7 A series of novel 1,2,4-triazole thioacetanilide derivatives has been designed, synthesized and evaluated for their anti-HIV activities in MT-4 cells. Half of these compounds showed moderate to potent activities against wild-type HIV-1 with an EC50 ranging from 38.0 μM to 4.08 µM. Among them, 2-(4-(2-fluorobenzyl)-5-isopropyl-4H-1,2,4-triazol- 3-ylthio)-N-(2-nitrophenyl)acetamide 7d was identified as the most promising compound (EC50 = 4.26 µM, SI = 49). However, no compound was active against HIV-2. The preliminary structure-activity relationships among the newly synthesized congeners are discussed. Topics: Acetanilides; Anti-HIV Agents; Cells, Cultured; Drug Design; Enzyme Activation; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles	2013

Article

Year

Arylazolylthioacetanilide. Part 11: design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

Medicinal chemistry (Shariqah (United Arab Emirates)), 2013, Volume: 9, Issue:7

A series of novel 1,2,4-triazole thioacetanilide derivatives has been designed, synthesized and evaluated for their anti-HIV activities in MT-4 cells. Half of these compounds showed moderate to potent activities against wild-type HIV-1 with an EC50 ranging from 38.0 μM to 4.08 µM. Among them, 2-(4-(2-fluorobenzyl)-5-isopropyl-4H-1,2,4-triazol- 3-ylthio)-N-(2-nitrophenyl)acetamide 7d was identified as the most promising compound (EC50 = 4.26 µM, SI = 49). However, no compound was active against HIV-2. The preliminary structure-activity relationships among the newly synthesized congeners are discussed.

Topics: Acetanilides; Anti-HIV Agents; Cells, Cultured; Drug Design; Enzyme Activation; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles

2013